Vaccine Code Set Update Publication Date: August 22, 2022
The individual filenames included in this distribution contain the publication date (20220822)
Release Notes: This release includes updates for all vaccine codes and maps. It does not include codes for Vaccine Information Statements (VIS). A separate release of codes for a new VIS edition is being published concurrently. The VIS will have also associated release notes.
General Note regarding this release: Codes with "Last Update" dates after July 24, 2022, and before August 20, 2022, reflect the changes and additions in this release. This release includes the following code set updates:
- COVID-19 vaccine codes added for bivalent booster vaccines including original strain and Omicron strains BA.4 and BA.5
- Monkeypox vaccine CVX Code updated
- Seasonal Influenza Vaccine Added
************************************************************************************************
1) COVID-19 Vaccine Code Set Updates
Codes have been published in anticipation for potential FDA Emergency Use Authorization (EUA) for new bivalent booster vaccines which include the original strain plus Omicron strain BA.4/BA.5. The additions include codes for both Pfizer and Moderna as shown in the tables below. The codes are provided to help providers prepare their systems in advance of product availability. The new or modified CVX codes and new Pre-EUA NDC codes and shown below. Note that there are currently no CPT codes available for these vaccines. AMA is anticipated to publish new codes late August which will be added to the CDC code set once available.
Table 1: Moderna Pre-EUA Bivalent Booster Codes
| CVX Code | CVX Long Description | CVX Short Description | Sale Proprietary Name | Product Description |
|---|
229 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25mL dose | Moderna COVID-19 Vaccine Bivalent Booster | Booster bivalent vaccine of Original and Omicron BA.4 & BA.5 COVID-19 strains
Same vial to be used to extract 0.5 mL adult dose for 12 + yrs and 0.25 mL dose for 6-11 yrs |
|---|
Unit of Sale NDC10 (UOS) | UoS Description | Unit of Use NDC10 (UOU) | UoU Presentation | MVX Code |
|---|
80777-282-99 | CARTON, 10 MULTI-DOSE VIALS | 80777-282-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | MOD |
|---|
Note: EUA for Moderna bivalent boosters may be rolled out with initial authorization for adults 18+ years, followed by authorizations for 12-17 years and 6-11 years.
Table 2: Pfizer Pre-EUA Bivalent Booster Codes
CVX Code | CVX Long Description | CVX Short Description | Sale Proprietary Name | Product Description |
|---|
300 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose | Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster
12 year and older
(GRAY CAP)
(Tris-sucrose formulation) | 30 mcg/0.3 mL dose
Original and Omicron BA.4 & BA.5 COVID-19 strains |
|---|
Unit of Sale NDC10 (UOS) | UoS Description | Unit of Use NDC10 (UOU) | UoU Presentation | MVX Code |
|---|
59267-0304-2 | CARTON, 10 MULTI-DOSE VIALS | 59267-0304-1 | VIAL, 2 mL, MULTI-DOSE VIAL
Each vial contains 6 doses of 0.3 mL | MOD |
|---|
59267-1404-2 | CARTON, 10 SINGLE-DOSE VIALS | 59267-1404-1 | VIAL, Each vial contains 1 dose of 0.3 mL |
|---|
CVX Code | CVX Long Description | CVX Short Description | Sale Proprietary Name | Product Description |
|---|
301 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose | Pfizer-BioNTech COVID-19 Vaccine Bivalent Booster
5 years through 11 years
(ORANGE CAP)
(Tris-sucrose formulation) | 10 mcg/0.2 mL dose
Original and Omicron BA.4 & BA.5 COVID-19 strains |
|---|
Unit of Sale NDC10 (UOS) | UoS Description | Unit of Use NDC10 (UOU) | UoU Presentation | MVX Code |
|---|
59267-0565-2 | CARTON, 10 MULTI-DOSE VIALS | 59267-0565-1 | VIAL, MULTI-DOSE
Each vial contains 10 doses of 0.2 mL | MOD |
|---|
2) Monkeypox vaccine CVX Code updated
On 8/9/2022 the FDA issued an EUA to allow intradermal administration of the JYNNEOS monkeypox vaccine in addition to the subcutaneous administration allowed under the BLA license. The FDA EUA and Recipient Fact Sheets can be found on the FDA site as follows:
EUA for Monkeypox JYNNEOS vaccine: Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply | FDA
Recipient Fact Sheet: Final Fact Sheet Monkeypox Jynneos 07292022 (fda.gov).
CDC resources for Monkeypox include:
The following vaccine code set updates have been made in this release to CVX Code 206 to address the new EUA for JYNNEOS:
- CVX Code 206 has been updated to support this additional administration option and to identify non-US tradenames for the JYNNEOS vaccine. The following fields have been updated:
- CVX Code Description (long): "Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection"
- CVX Code Description (short): "Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injection"
- CVX Note field: "Associated to FDA US Licensed product JYNNEOS, non-US tradenames IMVANEX, IMVAMUNE. Review CDC & FDA guidance for updates regarding administration"
Vaccine Group "Vaccinia" name change:
- The name for the vaccine group associated to both the monkeypox and smallpox vaccines has been changed from "VACCINIA" to "Orthopoxvirus". This will broaden and better represent the related viruses in this group. This is a modification to the existing vaccine group record. All CVX code associations to this vaccine group remain the same.
3) Seasonal Influenza Vaccines
- New 2022/2023 Seasonal Influenza Vaccines Additional vaccine codes for the 2022/2023 seasonal influenza vaccines have been added as shown in Table 3 below. Also updated is the website table "2022/2023 Seasonal Influenza Codes and Crosswalk". The table is available on the CDC website using the following link: https://www.cdc.gov/vaccines/programs/iis/code-sets.html
Table 3: Seasonal Influenza NDCs Added for the 2022/2023 Influenza Season
Proprietary Name | Labeler | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
FluMist Quadrivalent | MedImmune, LLC | 66019-309-10 | 66019-309-01 | APPLICATOR .2 mL | 149 | MED |
|---|
- 2021/2022 Seasonal Influenza NDCs Not Available for 2022/2023 Season
Table 4 below identifies two seasonal flu vaccine pediatric presentations which will not be produced for the 2022/2023 season. They have been removed from the online "2022/2023 Seasonal Influenza Codes and Crosswalk" on the CDC website.
Table 4: 2021/2022 Seasonal Influenza Vaccines Presentations Not Available for 2022/2023 season
Proprietary Name | Labeler | Presentation | CVX Code | MVX Code |
|---|
Afluria Quadrivalent | Seqirus PTY Lth. | SYRINGE, .25 ML | 161 | SEQ |
|---|
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | SYRINGE, .25 mL | 161 | PMC |
|---|
